Cantor Fitzgerald Raises CVS Health PT to $78, Keeps Overweight Rating

Cantor Fitzgerald Raises CVS Health PT to $78, Keeps Overweight Rating

Cantor Fitzgerald has reiterated its Overweight rating on CVS Health (NYSE:CVS) with an updated price target of $78.00. The healthcare giant is currently trading at $71.21 and boasts a market capitalization of $90.27 billion. The research firm maintains a positive outlook on CVS Health despite ongoing changes in the health insurance marketplace [2].

Cantor Fitzgerald noted that several health plans have notified states about reductions in their current coverage footprints. The firm believes these reductions will likely manifest as county-level decisions to exit exchange participation rather than complete state withdrawals. This approach preserves insurers’ rights to re-enter markets without facing the five-year ban that comes with full state exits. If CVS were to exit the market entirely, it would cause a significant membership shift since the company currently covers between 1.3 million and 1.4 million lives [2].

The research firm highlighted that CVS Health has demonstrated strong momentum with a 64% gain year-to-date. According to InvestingPro analysis, CVS appears undervalued based on its Fair Value metrics. The firm also noted recent positive analyst reviews. Baird upgraded CVS Health to Outperform, raising its price target to $82 due to opportunities in Medicare Advantage. Jefferies reiterated its Buy rating on CVS Health with a price target of $80, while Truist Securities also maintained a Buy rating with an $84 target [2].

In other recent news, Gilead Sciences faced a setback as CVS Caremark decided not to include its new HIV prevention drug, Yeztugo, in its commercial formularies. This decision by CVS, the largest pharmacy benefit manager in the U.S., was based on clinical, financial, and regulatory considerations. Despite this development, BMO Capital maintained its Outperform rating and a $130 price target on Gilead, indicating no broader concerns for the Yeztugo launch [2].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-ameriprise-financial-inc-has-50617-million-stake-in-cvs-health-corporation-cvs-2025-08-22/
[2] https://www.investing.com/news/analyst-ratings/cvs-health-stock-rating-reiterated-at-overweight-by-cantor-fitzgerald-93CH-4210747